Skip to main content
Fig. 1 | BMC Urology

Fig. 1

From: RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma

Fig. 1

RUNX3 pathway signature associated with IO/TKI therapy response and prognosis in RCC. (A) Expression of RUNX3 pathway signature in tumor tissues and peritumoral non-tumor tissues. P value, Wilcoxon rank-sum test. (B-C) Expression of RUNX3 pathway signature in RCC of different (B) TNM stages and (C) ISUP grades. P values, Kruskal-Wallis H test. (D) Pre- and post-treatment computed tomography images of patients with different response after IO/TKI therapy. (E) RUNX3 pathway signature in responders and non-responders of IO/TKI therapy. (F) Best tumor shrinkage rate after IO/TKI therapy in our ZS-MRCC cohort. (G-H) Progression-free survival according to RUNX3 pathway signature in the (G) ZS-MRCC cohort and the (H) JAVELIN-101 cohort. P values, Kaplan-Meier analysis, and log-rank test

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us